Isis Pharmaceuticals, Inc.

Eli Lilly and Company

Biothera Inc.

Hibercell, Inc.

Jeremy Graff

Eric E Swayze

Balkrishen Bhat

Kenneth W Dobie

Eric G Marcusson

Nandita Bose

Nadine Ottoson

Keith B Gorden

Xiaohong Qiu

Steven M Leonardo

Adria Bykowski Jonas

Ross Fulton

Takashi Kangas

Kathryn A Fraser

Anissa S H Chan

Richard Huhn

Mark Uhlik

Jamie Lowe

Ben Harrison

Anissa Sh Chan

Steven Leonardo

This disclosure provides, in one aspect, dosing strategies for soluble &#x3b2;-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble &#x3b2;-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Beta glucan immunopharmacodynamics

This disclosure relates to the combination of soluble &#x3b2;-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

&#x3b2;-glucan methods and compositions that affect the tumor microenvironment

The present invention relates to the combination of soluble &#x3b2;-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble &#x3b2;-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment

Oligomeric compounds, compositions and methods are provided for modulating the expression of eIF4E. The antisense compounds may be single- or double-stranded and are targeted to nucleic acid encoding eIF4E. Methods of using these compounds for modulation of eIF4E expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E are provided.

Modulation of eIF4E expression

The present invention provides methods of sensitizing lung cancer cells to cisplatin and inhibiting the growth of lung cancer tumors by employing a modified eIF-4E antisense oligonucleotide and cisplatin in combination.

Combination therapy for the treatment of cancer

Growing community of inventors

Indianapolis, IN, United States of America

Jeremy Graff